Rivastigmine modestly improves dementia associated with Parkinson's disease, but has important adverse effects.
نویسنده
چکیده
Patients: 541 people over the age of 50 years diagnosed with Parkinson’s disease (PD; UK PD Society Brain Bank criteria) and mild to moderate PD related dementia (DSM-IV; Mini Mental State Examination (MMSE) score 10–24). Exclusion criteria were: non-PD neurodegeneration; unstable medical comorbidity, disability, or dementia not related to PD; active, uncontrolled seizures; prior major depressive disorder; or use of anticholinergic drugs or cholinesterase inhibitor in previous month.
منابع مشابه
Rivastigmine: in Parkinson's disease dementia.
Rivastigmine is a carbamate-type dual inhibitor of brain acetyl- and butyrylcholinesterases that has been evaluated in the symptomatic treatment of patients with mild to moderate dementia associated with idiopathic Parkinson's disease. Oral rivastigmine 3-12 mg/day for 24 weeks was significantly more effective than placebo in ameliorating cognitive and functional decline, including attentional ...
متن کاملRivastigmine for dementia associated with Parkinson's disease.
BACKGROUND Cholinergic deficits are prominent in patients who have dementia associated with Parkinson's disease. We investigated the effects of the dual cholinesterase inhibitor rivastigmine in such patients. METHODS Patients in whom mild-to-moderate dementia developed at least 2 years after they received a clinical diagnosis of Parkinson's disease were randomly assigned to receive placebo or...
متن کاملThird degree atrioventricular block associated with treatment with rivastigmine transdermal patch
Rivastigmine transdermal patch is indicated for patients with Alzheimer's disease and dementia with Parkinson's disease. Rivastigmine, an acetylcholinesterase inhibitor, has several common adverse effects, mainly involving the gastrointestinal tract, but few cardiovascular adverse effects have been reported. This report presents two cases of patients presenting with 3(rd) degree atrioventricula...
متن کاملCognitive impairment in patients with Parkinson's disease: diagnosis, biomarkers, and treatment.
Dementia is one of the most common and important aspects of Parkinson's disease and has consequences for patients and caregivers, and has health-related costs. Mild cognitive impairment is also common and frequently progresses to dementia. The underlying mechanisms of dementia associated with Parkinson's disease are only partly known and no mechanism-based treatments are available. Both dysmeta...
متن کاملRivastigmine in the treatment of patients with Alzheimer’s disease
Impairment of attention and memory in patients with Alzheimer's disease (AD) is associated with significantly lower levels of acetylcholine. Inhibition of the breakdown of acetylcholine by blocking the enzymes acetylcholinesterase and butyrylcholinesterase with rivastigmine improves this cholinergic depletion. Thus rivastigmine administration provides established, effective, long-term symptomat...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید
ثبت ناماگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید
ورودعنوان ژورنال:
- Evidence-based mental health
دوره 8 2 شماره
صفحات -
تاریخ انتشار 2005